Skip to main content

Table 3 Incidence of adverse events

From: CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial

 CEOP/IVE/GDP (N = 51)CEOP (N = 51)
Grade 1–2Grade 3Grade 4Grade 1–2Grade 3Grade 4
Hematological event
 Neutropenia11 (22%)9 (18%)22 (43%)12 (24%)9 (18%)23 (45%)
 Thrombocytopenia12 (24%)2 (4%)2 (4%)10 (20%)1 (2%)3 (6%)
 Anemia34 (67%)4 (8%)1 (2%)31 (61%)5 (10%)0
 Febrile neutropenia/10 (20%)0/12 (24%)2 (4%)
Non-hematological events
 Infection*9 (18%)4 (8%)2 (4%)10 (20%)6 (12%)1 (2%)
 Nausea or vomiting15 (29%)2 (4%)019 (37%)1 (2%)0
 ALT or AST increase9 (18%)2 (4%)08 (16%)1 (2%)0
 Mucositis13 (25%)0015 (29%)1 (2%)0
 Fatigue37 (73%)1 (2%)034 (67%)1 (2%)0
 Headache13 (25%)1 (2%)05 (10%)1 (2%)0
  1. Data are n (%). All patients who received at least one dose of study drug were included in the safety analysis. *One patient in CEOP group died from severe infection after 1 cycle of treatment. ALT alanine aminotransferase, AST aspartate transaminase